{"transactions":[{"id":979202,"issuer":{"id":72153,"kind":"organization","name":"Mural Oncology plc","symbol":"MURA"},"owners":[{"id":72156,"kind":"person","name":"Keson-Brookes Maiken","position":1,"cik":"0001693805","reported_name":"Keson-Brookes Maiken","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-12-05T08:52:18.000Z","date":"2025-12-05","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":65000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Agreement, at the Effective Time each option to purchase ordinary shares of Issuer that had an exercise price per share that was equal to or greater than the Scheme Consideration was cancelled and ceased to be outstanding, and no Scheme Consideration was delivered in exchange for such options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Agreement, at the Effective Time each option to purchase ordinary shares of Issuer that had an exercise price per share that was equal to or greater than the Scheme Consideration was cancelled and ceased to be outstanding, and no Scheme Consideration was delivered in exchange for such options."}],"balance_after":0,"derivative":{"exercise_price":3.43,"expiration_date":"2035-03-02","underlying":"Ordinary Shares","underlying_shares":65000},"source":{"system":"sec-edgar","filing":"0001193125-25-308760","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1971543/000119312525308760/ownership.xml","form_type":"4"}},{"id":979201,"issuer":{"id":72153,"kind":"organization","name":"Mural Oncology plc","symbol":"MURA"},"owners":[{"id":72156,"kind":"person","name":"Keson-Brookes Maiken","position":1,"cik":"0001693805","reported_name":"Keson-Brookes Maiken","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-12-05T08:52:18.000Z","date":"2025-12-05","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":31200,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Agreement, at the Effective Time each option to purchase ordinary shares of Issuer that had an exercise price per share that was equal to or greater than the Scheme Consideration was cancelled and ceased to be outstanding, and no Scheme Consideration was delivered in exchange for such options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Agreement, at the Effective Time each option to purchase ordinary shares of Issuer that had an exercise price per share that was equal to or greater than the Scheme Consideration was cancelled and ceased to be outstanding, and no Scheme Consideration was delivered in exchange for such options."}],"balance_after":0,"derivative":{"exercise_price":5.39,"expiration_date":"2034-02-28","underlying":"Ordinary Shares","underlying_shares":31200},"source":{"system":"sec-edgar","filing":"0001193125-25-308760","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1971543/000119312525308760/ownership.xml","form_type":"4"}},{"id":979200,"issuer":{"id":72153,"kind":"organization","name":"Mural Oncology plc","symbol":"MURA"},"owners":[{"id":72156,"kind":"person","name":"Keson-Brookes Maiken","position":1,"cik":"0001693805","reported_name":"Keson-Brookes Maiken","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-12-05T08:52:18.000Z","date":"2025-12-05","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":54242,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Agreement, at the Effective Time each option to purchase ordinary shares of Issuer that had an exercise price per share that was equal to or greater than the Scheme Consideration was cancelled and ceased to be outstanding, and no Scheme Consideration was delivered in exchange for such options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Agreement, at the Effective Time each option to purchase ordinary shares of Issuer that had an exercise price per share that was equal to or greater than the Scheme Consideration was cancelled and ceased to be outstanding, and no Scheme Consideration was delivered in exchange for such options."}],"balance_after":0,"derivative":{"exercise_price":3.61,"expiration_date":"2033-12-13","underlying":"Ordinary Shares","underlying_shares":54242},"source":{"system":"sec-edgar","filing":"0001193125-25-308760","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1971543/000119312525308760/ownership.xml","form_type":"4"}},{"id":979199,"issuer":{"id":72153,"kind":"organization","name":"Mural Oncology plc","symbol":"MURA"},"owners":[{"id":72156,"kind":"person","name":"Keson-Brookes Maiken","position":1,"cik":"0001693805","reported_name":"Keson-Brookes Maiken","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Ordinary Shares","published_at":"2025-12-05T08:52:18.000Z","date":"2025-12-05","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":68834,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Pursuant to the terms of the Transaction Agreement (the \"Agreement\"), dated August 20, 2025, by and among the Issuer, XRA 5 Corp. (\"Sub\"), a Delaware corporation and wholly-owned subsidiary of XOMA Royalty Corporation, a Nevada corporation, Sub acquired all the issued and to be issued share capital of the Issuer (the \"Acquisition\") for a cash purchase price of $2.035 per share (the \"Scheme Consideration\"), as of December 5, 2025 (the \"Effective Time\")."},{"field":"shares","element":"transactionShares","label":"F2","text":"Includes the disposition of 62,203 unvested restricted stock units (\"RSUs\"). Pursuant to the Agreement, as of the Effective Time each RSU held by the Reporting Person that was outstanding as of immediately prior to the Effective Time (whether or not vested) was automatically cancelled and converted into the right to receive an amount equal to the Scheme Consideration."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the terms of the Transaction Agreement (the \"Agreement\"), dated August 20, 2025, by and among the Issuer, XRA 5 Corp. (\"Sub\"), a Delaware corporation and wholly-owned subsidiary of XOMA Royalty Corporation, a Nevada corporation, Sub acquired all the issued and to be issued share capital of the Issuer (the \"Acquisition\") for a cash purchase price of $2.035 per share (the \"Scheme Consideration\"), as of December 5, 2025 (the \"Effective Time\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Includes the disposition of 62,203 unvested restricted stock units (\"RSUs\"). Pursuant to the Agreement, as of the Effective Time each RSU held by the Reporting Person that was outstanding as of immediately prior to the Effective Time (whether or not vested) was automatically cancelled and converted into the right to receive an amount equal to the Scheme Consideration."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001193125-25-308760","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1971543/000119312525308760/ownership.xml","form_type":"4"}},{"id":1082874,"issuer":{"id":72153,"kind":"organization","name":"Mural Oncology plc","symbol":"MURA"},"owners":[{"id":72156,"kind":"person","name":"Keson-Brookes Maiken","position":1,"cik":"0001693805","reported_name":"Keson-Brookes Maiken","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Ordinary Shares","published_at":"2025-07-23T17:00:40.000Z","date":"2025-07-22","kind":"sale","planned":true,"acquired":false,"shares":2572,"price":2.48,"value":6378.56,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares automatically sold by the Reporting Person pursuant to a Rule 10b5-1 trading arrangement that was entered into by the Reporting Person on September 20, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.46 to $2.51. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 62,203 unvested restricted stock units."}],"balance_after":68834,"source":{"system":"sec-edgar","filing":"0000950170-25-097949","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1971543/000095017025097949/ownership.xml","form_type":"4"}},{"id":1083520,"issuer":{"id":72153,"kind":"organization","name":"Mural Oncology plc","symbol":"MURA"},"owners":[{"id":72156,"kind":"person","name":"Keson-Brookes Maiken","position":1,"cik":"0001693805","reported_name":"Keson-Brookes Maiken","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Ordinary Shares","published_at":"2025-07-22T17:00:05.000Z","date":"2025-07-18","kind":"sale","planned":true,"acquired":false,"shares":2158,"price":2.48,"value":5351.84,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 14, 2023. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement that includes a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1 that was entered into on December 22, 2023, and the sale does not represent a discretionary trade by the Reporting Person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 62,203 unvested restricted stock units."}],"balance_after":71406,"source":{"system":"sec-edgar","filing":"0000950170-25-097599","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1971543/000095017025097599/ownership.xml","form_type":"4"}},{"id":1223091,"issuer":{"id":72153,"kind":"organization","name":"Mural Oncology plc","symbol":"MURA"},"owners":[{"id":72156,"kind":"person","name":"Keson-Brookes Maiken","position":1,"cik":"0001693805","reported_name":"Keson-Brookes Maiken","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2025-03-05T16:49:15.000Z","date":"2025-03-03","kind":"grant","planned":true,"acquired":true,"shares":65000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"This option was granted on March 3, 2025. The option is scheduled to vest with respect to 25% of the underlying ordinary shares on March 1, 2026 and the remaining 75% of the underlying ordinary shares shall vest in 12 equal quarterly installments thereafter, subject to the reporting person's continued services with the Issuer."}],"balance_after":65000,"derivative":{"exercise_price":3.43,"expiration_date":"2035-03-02","underlying":"Ordinary Shares","underlying_shares":65000},"source":{"system":"sec-edgar","filing":"0000950170-25-033769","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1971543/000095017025033769/ownership.xml","form_type":"4"}},{"id":1223090,"issuer":{"id":72153,"kind":"organization","name":"Mural Oncology plc","symbol":"MURA"},"owners":[{"id":72156,"kind":"person","name":"Keson-Brookes Maiken","position":1,"cik":"0001693805","reported_name":"Keson-Brookes Maiken","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Ordinary Shares","published_at":"2025-03-05T16:49:15.000Z","date":"2025-03-05","kind":"sale","planned":true,"acquired":false,"shares":1469,"price":3.45,"value":5068.05,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"Represents shares automatically sold by the Reporting Person pursuant to a Rule 10b5-1 trading arrangement that was entered into by the Reporting Person on September 20, 2024."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 34,505 unvested restricted stock units"}],"balance_after":73564,"source":{"system":"sec-edgar","filing":"0000950170-25-033769","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1971543/000095017025033769/ownership.xml","form_type":"4"}},{"id":1223089,"issuer":{"id":72153,"kind":"organization","name":"Mural Oncology plc","symbol":"MURA"},"owners":[{"id":72156,"kind":"person","name":"Keson-Brookes Maiken","position":1,"cik":"0001693805","reported_name":"Keson-Brookes Maiken","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Ordinary Shares","published_at":"2025-03-05T16:49:15.000Z","date":"2025-03-04","kind":"sale","planned":true,"acquired":false,"shares":1262,"price":3.36,"value":4240.32,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on March 1, 2024. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement that includes a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1 that was entered into on December 22, 2023, and the sale does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.35 to $3.36. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 34,505 unvested restricted stock units"}],"balance_after":75033,"source":{"system":"sec-edgar","filing":"0000950170-25-033769","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1971543/000095017025033769/ownership.xml","form_type":"4"}},{"id":1223088,"issuer":{"id":72153,"kind":"organization","name":"Mural Oncology plc","symbol":"MURA"},"owners":[{"id":72156,"kind":"person","name":"Keson-Brookes Maiken","position":1,"cik":"0001693805","reported_name":"Keson-Brookes Maiken","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Ordinary Shares","published_at":"2025-03-05T16:49:15.000Z","date":"2025-03-03","kind":"grant","planned":true,"acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of ordinary shares issuable under 35,000 restricted stock units (\"RSUs\"). Each RSU represents the right to receive one ordinary share upon vesting. The RSUs are scheduled to vest with respect to 25% of the underlying ordinary shares on each of the first four anniversaries of March 1, 2025, subject to the reporting person's continued service with the Issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 34,505 unvested restricted stock units"}],"balance_after":76295,"source":{"system":"sec-edgar","filing":"0000950170-25-033769","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1971543/000095017025033769/ownership.xml","form_type":"4"}},{"id":1321928,"issuer":{"id":72153,"kind":"organization","name":"Mural Oncology plc","symbol":"MURA"},"owners":[{"id":72156,"kind":"person","name":"Keson-Brookes Maiken","position":1,"cik":"0001693805","reported_name":"Keson-Brookes Maiken","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Ordinary Shares","published_at":"2024-12-26T16:02:31.000Z","date":"2024-12-23","kind":"sale","planned":true,"acquired":false,"shares":2555,"price":3.27,"value":8354.85,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares automatically sold by the Reporting Person pursuant to a Rule 10b5-1 trading arrangement that was entered into by the Reporting Person on September 20, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.24 to $3.33. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 38,705 unvested restricted stock units."}],"balance_after":41295,"source":{"system":"sec-edgar","filing":"0000950170-24-140393","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1971543/000095017024140393/ownership.xml","form_type":"4"}},{"id":1451933,"issuer":{"id":72153,"kind":"organization","name":"Mural Oncology plc","symbol":"MURA"},"owners":[{"id":72156,"kind":"person","name":"Keson-Brookes Maiken","position":1,"cik":"0001693805","reported_name":"Keson-Brookes Maiken","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Ordinary Shares","published_at":"2024-07-18T16:04:17.000Z","date":"2024-07-18","kind":"sale","planned":true,"acquired":false,"shares":2157,"price":3.41,"value":7355.37,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 14, 2023. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement that includes a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1 that was entered into on December 22, 2023, and the sale does not represent a discretionary trade by the Reporting Person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 38,705 unvested restricted stock units."}],"balance_after":43850,"source":{"system":"sec-edgar","filing":"0000950170-24-084569","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1971543/000095017024084569/ownership.xml","form_type":"4"}},{"id":1603702,"issuer":{"id":72153,"kind":"organization","name":"Mural Oncology plc","symbol":"MURA"},"owners":[{"id":72156,"kind":"person","name":"Keson-Brookes Maiken","position":1,"cik":"0001693805","reported_name":"Keson-Brookes Maiken","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2024-03-04T17:18:23.000Z","date":"2024-03-01","kind":"grant","planned":false,"acquired":true,"shares":31200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on March 1, 2024. The option is scheduled to vest with respect to 25% of the underlying ordinary shares on March 1, 2025 and the remaining 75% of the underlying ordinary shares shall vest in 12 equal quarterly installments thereafter, subject to the reporting person's continued service with the Issuer."}],"balance_after":31200,"derivative":{"exercise_price":5.39,"expiration_date":"2034-02-28","underlying":"Ordinary Shares","underlying_shares":31200},"source":{"system":"sec-edgar","filing":"0000950170-24-024913","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1971543/000095017024024913/ownership.xml","form_type":"4"}},{"id":1603701,"issuer":{"id":72153,"kind":"organization","name":"Mural Oncology plc","symbol":"MURA"},"owners":[{"id":72156,"kind":"person","name":"Keson-Brookes Maiken","position":1,"cik":"0001693805","reported_name":"Keson-Brookes Maiken","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Ordinary Shares","published_at":"2024-03-04T17:18:23.000Z","date":"2024-03-01","kind":"grant","planned":false,"acquired":true,"shares":16800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of ordinary shares issuable under 16,800 restricted stock units (\"RSUs\"). Each RSU represents the right to receive one ordinary share upon vesting. The RSUs are scheduled to vest with respect to 25% of the underlying ordinary shares on each of the first four anniversaries of March 1, 2024, subject to the reporting person's continued service with the Issuer."}],"balance_after":46007,"source":{"system":"sec-edgar","filing":"0000950170-24-024913","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1971543/000095017024024913/ownership.xml","form_type":"4"}},{"id":1707630,"issuer":{"id":72153,"kind":"organization","name":"Mural Oncology plc","symbol":"MURA"},"owners":[{"id":72156,"kind":"person","name":"Keson-Brookes Maiken","position":1,"cik":"0001693805","reported_name":"Keson-Brookes Maiken","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2023-12-18T16:30:14.000Z","date":"2023-12-14","kind":"grant","planned":false,"acquired":true,"shares":54242,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on December 14, 2023. The option is scheduled to vest with respect to 25% of the underlying ordinary shares on July 17, 2024 and the remaining 75% of the underlying ordinary shares shall vest in 12 equal quarterly installments thereafter, subject to the reporting person's continued service with the Issuer."}],"balance_after":54242,"derivative":{"exercise_price":3.61,"expiration_date":"2033-12-13","underlying":"Ordinary Shares","underlying_shares":54242},"source":{"system":"sec-edgar","filing":"0000950170-23-071106","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1971543/000095017023071106/ownership.xml","form_type":"4"}},{"id":1707629,"issuer":{"id":72153,"kind":"organization","name":"Mural Oncology plc","symbol":"MURA"},"owners":[{"id":72156,"kind":"person","name":"Keson-Brookes Maiken","position":1,"cik":"0001693805","reported_name":"Keson-Brookes Maiken","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Ordinary Shares","published_at":"2023-12-18T16:30:14.000Z","date":"2023-12-14","kind":"grant","planned":false,"acquired":true,"shares":29207,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of ordinary shares issuable under 29,207 restricted stock units (\"RSUs\"). Each RSU represents the right to receive one ordinary share upon vesting. The RSUs are scheduled to vest with respect to 25% of the underlying ordinary shares on each of the first four anniversaries of July 17, 2023, subject to the reporting person's continued service with the Issuer."}],"balance_after":29207,"source":{"system":"sec-edgar","filing":"0000950170-23-071106","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1971543/000095017023071106/ownership.xml","form_type":"4"}},{"id":2419335,"issuer":{"id":116417,"kind":"organization","name":"Rubius Therapeutics, Inc.","symbol":"RUBY"},"owners":[{"id":72156,"kind":"person","name":"Keson-Brookes Maiken","position":1,"cik":"0001693805","reported_name":"Keson-Brookes Maiken","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Corp. Secretary"}}],"security":"Restricted Stock Units","published_at":"2022-02-01T21:19:00.000Z","date":"2022-01-31","kind":"grant","acquired":true,"shares":34500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The shares underlying the restricted stock units vest in four equal annual installments beginning on January 31, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The shares underlying the restricted stock units vest in four equal annual installments beginning on January 31, 2023."}],"balance_after":34500,"derivative":{"underlying":"Common Stock","underlying_shares":34500},"source":{"system":"sec-edgar","filing":"0001179110-22-000694","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1709401/000117911022000694/edgar.xml","form_type":"4"}},{"id":2419334,"issuer":{"id":116417,"kind":"organization","name":"Rubius Therapeutics, Inc.","symbol":"RUBY"},"owners":[{"id":72156,"kind":"person","name":"Keson-Brookes Maiken","position":1,"cik":"0001693805","reported_name":"Keson-Brookes Maiken","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Corp. Secretary"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-02-01T21:19:00.000Z","date":"2022-01-31","kind":"grant","acquired":true,"shares":143750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"25% of this option shall vest on January 31, 2023, then in 12 equal quarterly installments thereafter."}],"balance_after":143750,"derivative":{"exercise_price":6.75,"expiration_date":"2032-01-30","underlying":"Common Stock","underlying_shares":143750},"source":{"system":"sec-edgar","filing":"0001179110-22-000694","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1709401/000117911022000694/edgar.xml","form_type":"4"}},{"id":2419333,"issuer":{"id":116417,"kind":"organization","name":"Rubius Therapeutics, Inc.","symbol":"RUBY"},"owners":[{"id":72156,"kind":"person","name":"Keson-Brookes Maiken","position":1,"cik":"0001693805","reported_name":"Keson-Brookes Maiken","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Corp. Secretary"}}],"security":"Restricted Stock Units","published_at":"2022-02-01T21:19:00.000Z","date":"2022-01-29","kind":"exercise","acquired":false,"shares":8075,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares underlying the restricted stock units vest in four equal annual installments beginning on January 29, 2022."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The shares underlying the restricted stock units vest in four equal annual installments beginning on January 29, 2022."}],"balance_after":24225,"derivative":{"underlying":"Common Stock","underlying_shares":8075},"source":{"system":"sec-edgar","filing":"0001179110-22-000694","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1709401/000117911022000694/edgar.xml","form_type":"4"}},{"id":2419332,"issuer":{"id":116417,"kind":"organization","name":"Rubius Therapeutics, Inc.","symbol":"RUBY"},"owners":[{"id":72156,"kind":"person","name":"Keson-Brookes Maiken","position":1,"cik":"0001693805","reported_name":"Keson-Brookes Maiken","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Corp. Secretary"}}],"security":"Common Stock","published_at":"2022-02-01T21:19:00.000Z","date":"2022-02-01","kind":"sale","acquired":false,"shares":2732,"price":6.573,"value":17957.436,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting of the restricted stock units listed in Table II. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of minimum statutory tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary sale by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.57 to $6.71, inclusive. The reporting person undertakes to provide to Rubius Therapeutics, Inc., any security holder of Rubius Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":5343,"source":{"system":"sec-edgar","filing":"0001179110-22-000694","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1709401/000117911022000694/edgar.xml","form_type":"4"}},{"id":2419331,"issuer":{"id":116417,"kind":"organization","name":"Rubius Therapeutics, Inc.","symbol":"RUBY"},"owners":[{"id":72156,"kind":"person","name":"Keson-Brookes Maiken","position":1,"cik":"0001693805","reported_name":"Keson-Brookes Maiken","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Corp. Secretary"}}],"security":"Common Stock","published_at":"2022-02-01T21:19:00.000Z","date":"2022-01-29","kind":"exercise","acquired":true,"shares":8075,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock."}],"balance_after":8075,"source":{"system":"sec-edgar","filing":"0001179110-22-000694","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1709401/000117911022000694/edgar.xml","form_type":"4"}},{"id":2789281,"issuer":{"id":116417,"kind":"organization","name":"Rubius Therapeutics, Inc.","symbol":"RUBY"},"owners":[{"id":72156,"kind":"person","name":"Keson-Brookes Maiken","position":1,"cik":"0001693805","reported_name":"Keson-Brookes Maiken","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Corp. Secretary"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-03-15T20:28:03.000Z","date":"2021-03-15","kind":"exercise","acquired":false,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of this option vested on November 18, 2020, then in 12 equal quarterly installments thereafter."}],"balance_after":225000,"derivative":{"exercise_price":7.7,"expiration_date":"2029-11-28","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001179110-21-003441","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1709401/000117911021003441/edgar.xml","form_type":"4"}},{"id":2789280,"issuer":{"id":116417,"kind":"organization","name":"Rubius Therapeutics, Inc.","symbol":"RUBY"},"owners":[{"id":72156,"kind":"person","name":"Keson-Brookes Maiken","position":1,"cik":"0001693805","reported_name":"Keson-Brookes Maiken","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Corp. Secretary"}}],"security":"Common Stock","published_at":"2021-03-15T20:28:03.000Z","date":"2021-03-15","kind":"sale","acquired":false,"shares":25000,"price":20.2386,"value":505965.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale was effected pursuant to a Rule 10b5-1 trading plan, effective January 15, 2020, adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.69, inclusive. The reporting person undertakes to provide to Rubius Therapeutics, Inc., any security holder of Rubius Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001179110-21-003441","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1709401/000117911021003441/edgar.xml","form_type":"4"}},{"id":2789279,"issuer":{"id":116417,"kind":"organization","name":"Rubius Therapeutics, Inc.","symbol":"RUBY"},"owners":[{"id":72156,"kind":"person","name":"Keson-Brookes Maiken","position":1,"cik":"0001693805","reported_name":"Keson-Brookes Maiken","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Corp. Secretary"}}],"security":"Common Stock","published_at":"2021-03-15T20:28:03.000Z","date":"2021-03-15","kind":"exercise","acquired":true,"shares":25000,"price":7.7,"value":192500.0,"ownership":{"direct":true},"balance_after":25000,"source":{"system":"sec-edgar","filing":"0001179110-21-003441","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1709401/000117911021003441/edgar.xml","form_type":"4"}},{"id":2885869,"issuer":{"id":116417,"kind":"organization","name":"Rubius Therapeutics, Inc.","symbol":"RUBY"},"owners":[{"id":72156,"kind":"person","name":"Keson-Brookes Maiken","position":1,"cik":"0001693805","reported_name":"Keson-Brookes Maiken","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Corp. Secretary"}}],"security":"Restricted Stock Units","published_at":"2021-02-02T20:27:42.000Z","date":"2021-01-29","kind":"grant","acquired":true,"shares":32300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying the restricted stock units will vest in four equal annual installments beginning on January 29, 2022."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The shares underlying the restricted stock units will vest in four equal annual installments beginning on January 29, 2022."}],"balance_after":32300,"derivative":{"underlying":"Common Stock","underlying_shares":32300},"source":{"system":"sec-edgar","filing":"0001179110-21-001129","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1709401/000117911021001129/edgar.xml","form_type":"4"}},{"id":2885868,"issuer":{"id":116417,"kind":"organization","name":"Rubius Therapeutics, Inc.","symbol":"RUBY"},"owners":[{"id":72156,"kind":"person","name":"Keson-Brookes Maiken","position":1,"cik":"0001693805","reported_name":"Keson-Brookes Maiken","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Corp. Secretary"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-02-02T20:27:42.000Z","date":"2021-01-29","kind":"grant","acquired":true,"shares":142500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of this option shall vest on January 29, 2022, then in 12 equal quarterly installments thereafter."}],"balance_after":142500,"derivative":{"exercise_price":11.97,"expiration_date":"2031-01-28","underlying":"Common Stock","underlying_shares":142500},"source":{"system":"sec-edgar","filing":"0001179110-21-001129","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1709401/000117911021001129/edgar.xml","form_type":"4"}},{"id":3354341,"issuer":{"id":116417,"kind":"organization","name":"Rubius Therapeutics, Inc.","symbol":"RUBY"},"owners":[{"id":72156,"kind":"person","name":"Keson-Brookes Maiken","position":1,"cik":"0001693805","reported_name":"Keson-Brookes Maiken","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Corp. Secretary"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-12-03T20:50:09.000Z","date":"2019-11-29","kind":"grant","acquired":true,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of this option shall vest on November 18, 2020, then in 12 equal quarterly installments thereafter."}],"balance_after":250000,"derivative":{"exercise_price":7.7,"expiration_date":"2029-11-28","underlying":"Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0001104659-19-069692","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1709401/000110465919069692/a4.xml","form_type":"4"}},{"id":4436253,"issuer":{"id":4162,"kind":"organization","name":"uniQure N.V."},"owners":[{"id":72156,"kind":"person","name":"Keson-Brookes Maiken","position":1,"cik":"0001693805","reported_name":"Keson-Brookes Maiken","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Performance Share Unit","published_at":"2017-02-21T17:06:30.000Z","date":"2017-01-27","kind":"grant","acquired":true,"shares":43500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"Due to clerical error, the Form 4, as originally filed, incorrectly reports the number of options granted as 43,250 and the number of performance share units granted as 43,250. The Form 4, as amended by this Form 4/A, correctly reports such information."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Performance Shares Units of a maximum of 43,250 shares of the Company's Ordinary Shares were granted on January 27, 2017. The Board of Directors shall determine how many Performance Share Units are to be granted in conjunction with a review of certain performance goals associated with the grant. Any such Performance Share Units granted by the Board of Directors shall vest 100% on January 27, 2020."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Expiration date is not applicable."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F4","text":"Due to clerical error, the Form 4, as originally filed, incorrectly reports the number of options granted as 43,250 and the number of performance share units granted as 43,250. The Form 4, as amended by this Form 4/A, correctly reports such information."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Due to clerical error, the Form 4, as originally filed, incorrectly reports the number of options granted as 43,250 and the number of performance share units granted as 43,250. The Form 4, as amended by this Form 4/A, correctly reports such information."}],"balance_after":43500,"derivative":{"exercise_price":0,"underlying":"Ordinary Shares","underlying_shares":43500},"source":{"system":"sec-edgar","filing":"0001140361-17-008381","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1693805/000114036117008381/doc1.xml","form_type":"4/A","original_submission_date":"2017-01-31"}},{"id":4436252,"issuer":{"id":4162,"kind":"organization","name":"uniQure N.V."},"owners":[{"id":72156,"kind":"person","name":"Keson-Brookes Maiken","position":1,"cik":"0001693805","reported_name":"Keson-Brookes Maiken","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Stock Option (Right to Buy)","published_at":"2017-02-21T17:06:30.000Z","date":"2017-01-27","kind":"grant","acquired":true,"shares":43000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"Due to clerical error, the Form 4, as originally filed, incorrectly reports the number of options granted as 43,250 and the number of performance share units granted as 43,250. The Form 4, as amended by this Form 4/A, correctly reports such information."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Stock Option vests 25% on January 27, 2018 and 6.25% quarterly thereafter until fully vested."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F4","text":"Due to clerical error, the Form 4, as originally filed, incorrectly reports the number of options granted as 43,250 and the number of performance share units granted as 43,250. The Form 4, as amended by this Form 4/A, correctly reports such information."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Due to clerical error, the Form 4, as originally filed, incorrectly reports the number of options granted as 43,250 and the number of performance share units granted as 43,250. The Form 4, as amended by this Form 4/A, correctly reports such information."}],"balance_after":43000,"derivative":{"exercise_price":5.37,"expiration_date":"2027-01-27","underlying":"Ordinary Shares","underlying_shares":43000},"source":{"system":"sec-edgar","filing":"0001140361-17-008381","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1693805/000114036117008381/doc1.xml","form_type":"4/A","original_submission_date":"2017-01-31"}},{"id":4475440,"issuer":{"id":4162,"kind":"organization","name":"uniQure N.V."},"owners":[{"id":72156,"kind":"person","name":"Keson-Brookes Maiken","position":1,"cik":"0001693805","reported_name":"Keson-Brookes Maiken","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Performance Share Unit","published_at":"2017-01-31T15:28:17.000Z","date":"2017-01-27","kind":"grant","acquired":true,"shares":43250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Performance Shares Units of a maximum of 43,250 shares of the Company's Ordinary Shares were granted on January 27, 2017. The Board of Directors shall determine how many Performance Share Units are to be granted in conjunction with a review of certain performance goals associated with the grant. Any such Performance Share Units granted by the Board of Directors shall vest 100% on January 27, 2020."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Expiration date is not applicable."}],"balance_after":43250,"derivative":{"exercise_price":0,"underlying":"Ordinary Shares","underlying_shares":43250},"source":{"system":"sec-edgar","filing":"0001140361-17-003727","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1693805/000114036117003727/doc1.xml","form_type":"4"}},{"id":4475439,"issuer":{"id":4162,"kind":"organization","name":"uniQure N.V."},"owners":[{"id":72156,"kind":"person","name":"Keson-Brookes Maiken","position":1,"cik":"0001693805","reported_name":"Keson-Brookes Maiken","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Stock Option (Right to Buy)","published_at":"2017-01-31T15:28:17.000Z","date":"2017-01-27","kind":"grant","acquired":true,"shares":43250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Stock Option vests 25% on January 27, 2018 and 6.25% quarterly thereafter until fully vested."}],"balance_after":43250,"derivative":{"exercise_price":5.37,"expiration_date":"2027-01-27","underlying":"Ordinary Shares","underlying_shares":43250},"source":{"system":"sec-edgar","filing":"0001140361-17-003727","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1693805/000114036117003727/doc1.xml","form_type":"4"}}]}